Aggressive investor
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$IGXT New drug tablet Versafilm gets rid of migraines in 30 seconds
http://video.foxbusiness.com/v/4163821880001/new-drug-tablet-versafilm-gets-rid-of-migraines-in-30-seconds/?#sp=show-clips
$IGXT New drug tablet Versafilm gets rid of migraines in 30 seconds
http://video.foxbusiness.com/v/4163821880001/new-drug-tablet-versafilm-gets-rid-of-migraines-in-30-seconds/?#sp=show-clips
Didn't know that. Found CYNAF working on Parkinson's Disease
Cynapsus Therapeutics Provides Clinical and Regulatory Update for APL-130277 for the Acute Rescue of OFF Motor Symptoms of Parkinson's Disease
http://www.stockhouse.com/news/press-releases/2015/03/11/cynapsus-therapeutics-provides-clinical-and-regulatory-update-for-apl-130277#ezCmppD8Uewq3yhW.99
$IGXT New drug tablet Versafilm gets rid of migraines in 30 seconds
http://video.foxbusiness.com/v/4163821880001/new-drug-tablet-versafilm-gets-rid-of-migraines-in-30-seconds/?#sp=show-clips
$IGXT New drug tablet Versafilm gets rid of migraines in 30 seconds
http://video.foxbusiness.com/v/4163821880001/new-drug-tablet-versafilm-gets-rid-of-migraines-in-30-seconds/?#sp=show-clips
$DVAX Analyst Rating Update
http://www.woodbridgedaily.com/dynavax-technologies-corporation-analyst-rating-update/32764/
Brokerages Set $35.33 Price Target for Dynavax Technologies (NASDAQ:DVAX)
http://www.wkrb13.com/markets/546979/brokerages-set-35-33-price-target-for-dynavax-technologies-nasdaqdvax/
Brokerages Set $35.33 Price Target for Dynavax Technologies (NASDAQ:DVAX)
http://www.wkrb13.com/markets/546979/brokerages-set-35-33-price-target-for-dynavax-technologies-nasdaqdvax/
Analysts Give Consensus Recommendation of “Strong Buy” to Dynavax Technologies (NASDAQ:DVAX)
http://www.lulegacy.com/2015/04/04/analysts-give-consensus-recommendation-of-strong-buy-to-dynavax-technologies-nasdaqdvax/432235/
Form 8-K $IGXT Mar 31, 2015
http://www.streetinsider.com/SEC+Filings/Form+8-K+IntelGenx+Technologies+For%3A+Mar+31/10417316.html
$IGXT to Report 2014 Annual Results and Provide Corporate Development Update on March 31, 2015 http://www.intelgenx.com/investors/pressreleases/2015/2015-03-23.html
$IGXT to Report 2014 Annual Results and Provide Corporate Development Update on March 31, 2015 http://www.intelgenx.com/investors/pressreleases/2015/2015-03-23.html
any thought?
file:///C:/Users/shossain/Downloads/Edison_MediciNova%20(MNOV)_%203-26-2015.pdf
Ticker: NASDAQ:MNOV
Pipelines: http://medicinova.com/clinical-development/development-pipeline/
DVAX fast approaching to $30, maybe by the end of today
DVAX fast approaching to $30, maybe by the end of today
IntelGenx to Report 2014 Annual Results and Provide Corporate Development Update on March 31, 2015
Read more at http://www.stockhouse.com/news/press-releases/2015/03/23/intelgenx-to-report-2014-annual-results-and-provide-corporate-development#fUevO49fDhcHfAp5.99
IntelGenx to Report 2014 Annual Results and Provide Corporate Development Update on March 31, 2015
http://www.stockhouse.com/news/press-releases/2015/03/23/intelgenx-to-report-2014-annual-results-and-provide-corporate-development#fUevO49fDhcHfAp5.99
Revisiting 2 Small Cap Biotech Gems
http://seekingalpha.com/article/3021486-revisiting-2-small-cap-biotech-gems
Revisiting 2 Small Cap Biotech Gems
http://seekingalpha.com/article/3021486-revisiting-2-small-cap-biotech-gems
$DVAX on track short term goal $30.00
$IGXT to Report 2014 Annual Results and Provide Corporate Development Update on March 31, 2015 http://web.tmxmoney.com/article.php?newsid=74288533&qm_symbol=IGX
$IGXT to Report 2014 Annual Results and Provide Corporate Development Update on March 31, 2015
http://web.tmxmoney.com/article.php?newsid=74288533&qm_symbol=IGX
$DVAX starting to show continued strength. Big Hepatitis B trial should be complete and announced by end of 2015 and could be catalyst
DVAX Overweight. And $35 allows room for their next upgrade to $60
DVAX Overweight. And $35 allows room for their next upgrade to $60
was out last week. will revisit once dust clear.
strong pipeline!!!!
Dynavax Technologies Upgraded by JPMorgan Chase & Co. to Overweight (DVAX)
http://sleekmoney.com/dynavax-technologies-upgraded-by-jpmorgan-chase-co-to-overweight-dvax/181340/
Pre-market on fire
Dynavax Technologies Upgraded by JPMorgan Chase & Co. to Overweight (DVAX)
http://sleekmoney.com/dynavax-technologies-upgraded-by-jpmorgan-chase-co-to-overweight-dvax/181340/
should be DVAX
lol
Great Catch
$DVAX pre market looking strong. Short term goal $30.
Mid term - by October 2015 $60 plus
Long Term by Q1, 2016 - sky has no limit
$DVAX The Superior Player In Hepatitis B Vaccination
http://seekingalpha.com/article/2985246-dynavax-the-superior-player-in-hepatitis-b-vaccination
$DVXS's next leg up which will have us trading in the $25-$30 range in the next 4-6 weeks. Dynavax Heplisav phase III trial risk is reduced even more so which will likely cause the stock to march higher
Thanks. I think we have here the classic RED DIXIE CUP AND HANDLE formation.
$DVAX The Superior Player In Hepatitis B Vaccination
http://seekingalpha.com/article/2985246-dynavax-the-superior-player-in-hepatitis-b-vaccination
$DVAX The Superior Player In Hepatitis B Vaccination
http://seekingalpha.com/article/2985246-dynavax-the-superior-player-in-hepatitis-b-vaccination